tradingkey.logo

Edwards Lifesciences Corp

EW
查看詳細走勢圖
84.810USD
-0.030-0.04%
收盤 12/18, 16:00美東報價延遲15分鐘
49.25B總市值
36.12本益比TTM

Edwards Lifesciences Corp

84.810
-0.030-0.04%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.04%

5天

+0.68%

1月

+0.92%

6月

+14.64%

今年開始到現在

+14.56%

1年

+16.48%

查看詳細走勢圖

TradingKey Edwards Lifesciences Corp股票評分

單位: USD 更新時間: 2025-12-18

操作建議

Edwards Lifesciences Corp當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名8/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價94.75。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Edwards Lifesciences Corp評分

相關信息

行業排名
8 / 208
全市場排名
55 / 4585
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 34 分析師
買入
評級
94.747
目標均價
+12.37%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Edwards Lifesciences Corp亮點

亮點風險
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入5.44B美元
估值高估
公司最新PE估值36.11,處於3年歷史高位
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉7.64K股

Edwards Lifesciences Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Edwards Lifesciences Corp簡介

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
公司代碼EW
公司Edwards Lifesciences Corp
CEOZovighian (Bernard J)
網址https://www.edwards.com

常見問題

Edwards Lifesciences Corp(EW)的當前股價是多少?

Edwards Lifesciences Corp(EW)的當前股價是 84.810。

Edwards Lifesciences Corp 的股票代碼是什麼?

Edwards Lifesciences Corp的股票代碼是EW。

Edwards Lifesciences Corp股票的52週最高點是多少?

Edwards Lifesciences Corp股票的52週最高點是87.890。

Edwards Lifesciences Corp股票的52週最低點是多少?

Edwards Lifesciences Corp股票的52週最低點是65.940。

Edwards Lifesciences Corp的市值是多少?

Edwards Lifesciences Corp的市值是49.25B。

Edwards Lifesciences Corp的淨利潤是多少?

Edwards Lifesciences Corp的淨利潤為4.17B。

現在Edwards Lifesciences Corp(EW)的股票是買入、持有還是賣出?

根據分析師評級,Edwards Lifesciences Corp(EW)的總體評級為買入,目標價格為94.747。

Edwards Lifesciences Corp(EW)股票的每股收益(EPS TTM)是多少

Edwards Lifesciences Corp(EW)股票的每股收益(EPS TTM)是2.348。
KeyAI